MARC Record from harvard_bibliographic_metadata

LEADER: 03946cam a22003738a 4500
001 011934950-7
005 20090416141706.0
008 080930s2009 njuaf b 001 0 eng
015 $aGBA8B6716$2bnb
016 7 $a014771912$2Uk
020 $a9781588297372 (hbk.)
020 $a1588297373 (hbk.)
035 0 $aocn261948167
040 $aUKM$cUKM$dMMU
050 00 $aRC280.K5$bR466 2009
060 00 $a2009 D-966
060 10 $aWJ 358$bR39365 2009
082 04 $a616.99461$222
245 00 $aRenal cell carcinoma :$bmolecular targets and clinical applications /$cRonald M. Bukowski, Robert A. Figlin, Robert J. Motzer, editors.
250 $a2nd ed.
260 $aTotowa, N.J. :$bHumana Press,$cc2009.
300 $axvii, 507 p., [12] p. of plates :$bill. (some col.) ;$c24 cm.
500 $aPrevious ed.: 2000.
504 $aIncludes bibliographical references and index.
505 0 $aTargeted therapy for metastatic renal call carcinoma: overview -- Molecular genetics in inherited renal cell carcinoma: identification of targets in the hereditary syndromes -- Molecular targets in renal tumors: pathologic assessment -- Interferons and interleukin-2: molecular basis of activity and therapeutic results -- The molecular biology of kidney cancer and its clinical translation into treatment strategies -- VEGF: biologic aspects and clinical approaches -- VEGF and PDGF receptors: biologic relevance and clinical approaches to inhibition -- Sunitinib and axitinib in renal cell carcinoma -- Sorafenib in renal cell carcinoma -- Additional tyrosine kinase inhibitors in renal cell carcinoma -- Integrin [alpha]5[beta]1 as a novel therapeutic target in renal cancer -- Carbonic anhydrase IX: biology and clinical approaches -- Monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma: biological and clinical studies -- Chemokines in renal cell carcinoma: implications for tumor angiogenesis and metastasis -- P13K/Akt/mTOR pathway: a growth and proliferation pathway -- EGFR and HER2: relevance in renal cell carcinoma -- Proteasome-NF[kappa]B signaling pathway: relevance in RCC -- The role of hepatocyte growth factor pathway signaling in renal cell carcinoma -- Smac/DIABLO: a proapoptotic molecular target in renal cell cancer -- EphA2: a novel target in renal cell carcinoma -- Restoring host antitumoral immunity: how coregulatory molecules are changing the approach to the management of renal cell carcinoma -- The role of gangliosides in renal cell carcinoma -- Tumour necrosis factor: misnomer and therapeutic target -- Molecular markers for predicting prognosis of renal cell carcinoma -- Adjuvant therapy for renal cell carcinoma: targeted approaches.
520 $aIn the second edition of their critically acclaimed book, Ronald Bukowski, Robert Motzer, and Robert Figlin have thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. A panel of internationally renowned contributors explores the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. The discussion includes the specific biology of selected target molecules or receptors and the various agents that inhibit these targets, including full chapters devoted to drugs that selectively inhibit receptor tyrosine kinases, such as sunitinib and axitinib. Further attention is paid to leading-edge strategies that target and inhibit tumor associated angiogenesis and block the vascular endothelial growth factor pathway. This book is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited.
650 0 $aRenal cell carcinoma.
650 12 $aCarcinoma, Renal Cell.
650 22 $aKidney Neoplasms.
700 1 $aBukowski, Ronald M.
700 1 $aFiglin, Robert A.
700 1 $aMotzer, Robert J.
988 $a20090414
906 $0OCLC